CA-BEHAVIOSEC
BehavioSec, the first vendor to pioneer behavioral biometrics, is attending Money20/20 Europe on June 3-5, 2019 in Amsterdam, Netherlands at the Amsterdam RAI. Money20/20 focuses on the mission of creating a simpler, fairer, faster and more inclusive financial system for individuals, businesses and society as a whole, bringing together more than 350 speakers to deliver the next frontier of Financial Services. BehavioSec CEO Neil Costigan will join the panel discussion, “The Changing Nature of Attacks and Attackers,” where he will discuss cybersecurity and risk management in an age where online commerce and trust are threatened by cybercrime threats continually bypassing traditional password authentication and anti-fraud measures.
Money20/20 attendees can visit BehavioSec at booth H92 throughout the event. BehavioSec will meet with customers and industry partners, brief media and analysts and present demos of the company’s Behavioral Biometrics Software Platform . Already in use with some of the biggest global brands in FinTech and financial services, BehavioSec’s software provides continuous online authentication of account holders by analyzing their unique physical behaviors, like typing patterns, cursor movements and touchscreen inputs.
“Traditional, one-time authentication measures like thumbprints and passwords can no longer protect and enable digital transformation in the financial services sector,” said Costigan. “With today’s constantly evolving attacks bypassing even once reliable multi-factor authentication methods, financial service organizations must find new ways to prevent fraud and cyber attacks without slowing down usability and functionality. Presenting at Money20/20 gives us the opportunity to show the success of behavioral biometrics in combating account takeover fraud in this new threat landscape.”
Join BehavioSec’s Neil Costigan at the following session:
|
What: |
The Changing Nature of Attacks and Attackers |
|
|
Who: |
Neil Costigan, CEO, BehavioSec (Speaker) | |
| Dr. Yinglian Xie, Co-Founder and CEO, DataVisor (Speaker) | ||
| Max Laemmle, Founder and CEO, Fraugster Limited (Speaker) | ||
| Andrew Jamieson, Technology & Security Director, UL (Moderator) | ||
|
When: |
Wednesday, June 5, 2019 from 14:10 p.m. to 14:50 p.m. CEST | |
|
Where: |
Industry Transmutation Stage at RAI Amsterdam, Amsterdam, Netherlands |
As CEO of BehavioSec, Costigan leads the company’s work delivering innovative behavioral biometric technology protecting consumer transactions, payments and financial firms from fraud and theft. He has more than 25 years’ of entrepreneurial and technical leadership experience in venture-backed startups, and global technology corporations spanning the U.S., and EU. A cryptographer by training, his career expanded to include software development, executive leadership and entrepreneurship. He holds an extensive portfolio of patents and serves as Principal Investigator for BehavioSec’s U.S. DOD DARPA projects.
Prior to BehavioSec, Costigan was VP for R&D at Smart Card manufacturer Gemplus (now Gemalto) and Co-founder/CTO at PKI specialists Celo Communications (Celo). Neil holds a PhD (2009) for his thesis on Elliptic Curve Cryptography on Modern Processor Architectures and has developed a number of commercial security applications. He frequently presents and presents on innovation, cryptography and network security.
Follow BehavioSec for more details and the latest in behavioral biometrics technology:
About BehavioSec
BehavioSec is the first vendor to pioneer behavioral biometrics. The company’s Behavioral Biometrics Platform is widely deployed across Global 2000 companies for its proven ability to dramatically reduce account fraud and data theft. Founded in 2008 out of groundbreaking academic research, BehavioSec technology allows companies to continuously verify digital identities with superior precision, in real-time. Strengthened with the leadership of serial entrepreneurs and experienced industry professionals, the BehavioSec team now spans the world, providing security while preserving a rich digital experience throughout web and mobile apps. BehavioSec is the only enterprise-grade vendor used in global deployments with some of the largest companies, reducing manual review whilst safeguarding millions of users and billions of transactions. BehavioSec investors include Forgepoint Capital, Cisco, ABN AMRO, Conor Ventures and Octopus Ventures. BehavioSec is headquartered in San Francisco, CA and has global operations throughout Europe and Asia Pac. For more information, visit www.behaviosec.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190531005032/en/
Contact:
Media Contact: Savannah Young +1 (703) 877-8111 pr@behaviosec.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Original “Titanic Cherub” From James Cameron’s Epic Film Heads to Auction December 9 & 1024.11.2025 21:48:00 CET | Press release
Iconic Hollywood Artifact Indelibly Linked with “Jack & Rose” Portrayed by Kate Winslet and Leonardo DiCaprio One of the most recognizable and beloved set pieces from James Cameron’s Titanic heads to auction on December 9 &10 —the original Grand Staircase Cherub, seen in multiple scenes of the 1997 blockbuster, including the pivotal moment when Jack and Rose meet in front of the First Class Dining Room and the climactic moment when the Atlantic Ocean bursts through the skylight and floods the staircase, and cherub. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124056883/en/ The iconic “cherub” with Leonardo DiCaprio & Kate Winslet in James Cameron’s “TITANIC”. The ornate fixture—crafted for the full-scale recreation of Titanic’s Grand Staircase—was gifted by the production to Martin Biallas, CEO of SEE Global Entertainment, whose immersive exhibitions have brought the world’s most famous ship to millions of fans. It now
Access Advance Announces Major Growth in Its HEVC and VVC Patent Pools24.11.2025 16:10:00 CET | Press release
Access Advance LLC today announced significant expansions of both its HEVC Advance and VVC Advance Patent Pools during the second and third quarters of 2025, underscoring continued industry confidence in the company's balanced and transparent approach to video codec licensing. This growth follows the successful January 2025 launch of Access Advance's Video Distribution Patent ("VDP") Pool, demonstrating the company's expanding role in comprehensive video codec patent licensing solutions. Among the many highlights, Sharp Corporation joined the HEVC Advance Patent Pool as a Licensor, bringing valuable intellectual property assets to the pool's already extensive patent portfolio. Additionally, Huawei Technologies Co., Ltd., already an HEVC Advance Licensor and Licensee, expanded its collaboration with Access Advance by joining the VVC Advance Patent Pool as a Licensee. HP Inc. also expanded its license to include the VVC Advance Patent Pool after previously joining HEVC Advance in 2024, w
Microsize and Schedio Group to Acquire Lonza’s Micro-Macinazione Site in Switzerland24.11.2025 15:05:00 CET | Press release
Microsize, a leading CDMO specializing in particle size reduction and control technologies, today announced it has signed an agreement to acquire Micro-Macinazione (Mic Mac), a dedicated micronization facility in Monteggio, Switzerland, from Lonza. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124545344/en/ The agreement represents Microsize’s second acquisition from Lonza, following the successful 2022 divestment of its Quakertown, Pennsylvania site. In this transaction, Schedio Group – a Swiss-based provider of jet mills, isolators, spray dryers, and engineering services – is investing alongside Microsize to strengthen and localize its operational base in Europe, advancing a shared vision to lead the next generation of integrated particle engineering solutions. With more than 30 years of experience, Mic Mac has served the pharmaceutical industry with proven GMP-compliant jet milling and micronization capabilities for b
Hytera to Debut S1 E at PMRExpo 202524.11.2025 14:17:00 CET | Press release
Hytera, a leading global provider of critical communications technologies and solutions, today introduced the S1 E, a business-ready, palm-sized two-way radio designed specifically for the retail sector, expanding the portfolio of S Series and providing one more option for retail users to choose for their daily operations. The S1 E will make its debut at PMRExpo, the Europe's premier trade fair for secure, mission- and business-critical communication, taking place from November 25th to 27th, 2025, at Koelnmesse in Cologne, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124768341/en/ Hytera New Released Licence-free Analogue Business Radio S1 E Adhering to the S Series’ signature design language, the S1 E combines a stylish, modern, and minimalist aesthetic with practical functionality. Weighing under 85g, the S1 E provides all-day wearing comfort without tugging or weighing down uniforms. Key enhancements and sta
Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis24.11.2025 14:00:00 CET | Press release
Cladribine capsules have the potential to be the first oral treatment for people living with rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia GravisCladribine capsules has received Fast Track designation and Orphan Drug Designation by the US FDAMerck has established an MG patient council to provide insights on how to best meet the needs of patients in the gMG rare disease community Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia Gravis (gMG). In June 2023, the FDA granted Orphan Drug Designation for cladribine capsules for the treatment of gMG. In addition, the Company is actively collaborating with patient organizations and Ad Scientiam, a medical technology company, to support a patient-directed approach to the future management of gMG. If approved
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom